An Investment Update: Zion Oil & Gas, Inc. (ZN), PDL BioPharma, Inc. (PDLI)

Zion Oil & Gas, Inc. (NASDAQ:ZN) has its shares plummet by -75.83% or $0.91 from its all-time high of $1.2. The drop in the price of the shares saw it stand at $0.29 per share. ZN has been trading at a low of $0.12 over the past one year but it surged by 141.67% or $0.17 to reach the $0.29 mark. Following the massive rise in stock price, ZN received more attention from investors and analysts. On Wednesday, the stock dipped by -24.14%, which caused investors and analysts to worry about it. Following the plunge in price, the ZN beta stands at 0.1, implying that its volatility level has gone down by 0.9 back of the general market. A look at the stock’s 200-day moving average shows that it is -18.79% below while its 50-day moving average shows that it is currently 52.24% above. Compared to 26.93% average daily volatility of past month, the stock’s average volatility for this week has increased by 33.45 as the volatility level currently stands at 60.38%.

Over the past seven days, the stock has witnessed a price surge by 70.28%. This massive rise in stock price has caught the attention of both investors and market traders. The stock has performed poorly over the past 52 weeks, dropping by -28.33% during that time frame and is now up by 70.28% since this point this year. ZN has surged by 89.74% over the past 30 days, with its equity price gaining% of its value over the past ninety days. These figures add up to see the stock record a shortfall of -18.36% over the past six months.

The stock’s technical analysis reveals that its 14-day Relative Strength Index (RSI) is currently in a neutral position as it was able to attain 56.29 points. The trading volume now standing at 26599131 shares. The increase of 23739131 shares in trading volume shows that traders and investors have shown more interest in the stock over the past few weeks. During that trading session, the average trading volume of ZN was 2860000 shares, which is more than 9.3 times higher than its usual trading volume.

The stock is currently oversold as its Stochastic Oscillator (%D) is at 13.4%, which implies that a jump in price could be experienced soon. Its shares P/S ratio is below the industry average and below the wider market, as PDLI’s P/S ratio currently stands at 3.38. The stock’s estimated price-earnings (P/E) multiple is 28.26 which is also above the 12-month price-earnings (P/E) which stands at 0. PDL BioPharma, Inc. has experienced a fall in its earnings, recording an decrease rate of -18% in each quarter over the past five years.

The stock has an average rating of 0 which means that it has been rated as a Buy by most analysts. The stock is being covered by 1 analysts who gave a consensus recommendation of 0 which implies that it is currently in a bull/bear situation. Reuters looked into analysts covering PDL BioPharma, Inc., and 1 of them believe that the stock is a Hold at the moment. 0 of the analysts rated it as a Buy or a Strong Buy while the remaining analysts (0) rated it as a sell at the moment.